Okada Yosuke
   Department   School of Medicine  Internal Medicine(1), Clinical Medical Sciences
   Position  
Article types review
Language English
Peer review Peer reviewed
Title Comparative analysis of the effects of alogliptin and vildagliptin on glucose metabolism in type 2 diabetes mellitus.
Journal Formal name:Endocrine journal
Abbreviation:Endocr J
ISSN code:13484540/09188959
Domestic / ForeginForegin
Volume, Issue, Page 64(2),179-189頁
Author and coauthor Tanaka Kenichi, Okada Yosuke, Mori Hiroko, Miyazaki Megumi, Kuno Fumi, Sonoda Satomi, Sugai Kei, Hajime Maiko, Kurozumi Akira, Narisawa Manabu, Torimoto Keiichi, Arao Tadashi, Mine Shinichiro, Tanaka Yoshiya
Publication date 2017/02
Summary The aim of this 24-week, prospective randomized open-label study was to compare the effects of alogliptin and vildagliptin on glucose control, renal function, and lipid metabolism. In Study 1, DPP-4 inhibitor-naive type 2 diabetes (T2DM) were randomly assigned to alogliptin 25 mg/day or vildagliptin 50 mg twice daily. In Study 2, T2DM on treatment with 50 mg/day sitagliptin were switched to either 25 mg/day alogliptin or 50 mg twice daily vildagliptin. The primary endpoint was change in glycosylated hemoglobin (HbA1c) level at 24 weeks, while the secondary endpoints were changes in urinary albumin excretion and low-density lipoprotein cholesterol (LDL-C) levels at 24 weeks. In Study 1, HbA1c levels changed at 24-week by -0.5±0.7% in the alogliptin group (p=0.002, relative to baseline) and -0.7±0.9% in the vildagliptin group (p=0.001, relative to baseline), and the extent of these changes were comparable between the two groups (p=0.219). The decrease in log urinary albumin excretion was more significant in the vildagliptin group (p=0.008). In Study 2, HbA1c levels at 24-week changed by 0.2±0.7% in the switch-to-alogliptin group (p=0.007) and 0.0±0.6% in the switch-to-vildagliptin group (p=0.188), indicating a significant difference between the groups (p=0.003). In both studies, the changes in LDL-C levels were comparable between the two groups. The two drugs had comparable glucose-lowering effects in DPP-4 inhibitor-naive patients but the effect was more pronounced for vildagliptin in patients switched from sitagliptin. The results may point to subtle yet important differences between the two DPP-4 inhibitors. This trial was registered with UMIN (no. #000019022).
DOI 10.1507/endocrj.EJ16-0341
PMID 27840383